In our population, we could only treat BRAF wild-type melanoma in the 1L setting with immunotherapy monotherapy (mainly anti-PD-1) and the BRAF-mutated melanoma with BRAFi/MEKi. This evidence concerns the gene PDCD1 and melanoma.